Caregen KRX:214370KOSDAQ
케어젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked15since Sep 11
In Q2 2026, Caregen reported revenue of ₩18.8bn, up 3.7% year on year, and operating profit of ₩5.2bn. Caregen (케어젠) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Op. margin 20%+ Insider buying Dividend cut Screener
Caregen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩18.8bn | +3.7% | ₩5.2bn margin 27.9% | ₩4.3bn |
| Q1 2026 | ₩22.7bn | +6.6% | ₩10.2bn margin 45.0% | ₩11.7bn |
| Q4 2025 derived | ₩16.3bn | -23.6% | −₩7.1bn margin −43.4% | −₩3.3bn |
| Q3 2025 | ₩17.1bn | -15.9% | ₩9.9bn margin 57.7% | ₩10.2bn |
| Q2 2025 | ₩18.1bn | -11.5% | ₩7.4bn margin 41.1% | ₩4.8bn |
| Q1 2025 | ₩21.3bn | +4.1% | ₩10.2bn margin 47.7% | ₩8.4bn |
| Q4 2024 derived | ₩21.4bn | +22.5% | ₩6.1bn margin 28.7% | ₩5.1bn |
| Q3 2024 | ₩20.3bn | +8.6% | ₩12.7bn margin 62.4% | ₩11.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Caregen top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Caregen news Korean headlines
-
Major[케어젠 딥시크②]美 FDA 넘은 '프로지스테롤' 韓 식약처 도전 4년째 공회전
1 more on this story · 1 outlets
- [케어젠 딥시크②]美 FDA 넘은 '프로지스테롤' 韓 식약처 도전 4년째 공회전이데일리 · Oct 7 07:01
-
케어젠, 글로벌 파트너 한자리…해외 판매 확대 논의
2 more on this story · 2 outlets
- 케어젠, 글로벌 파트너와 해외 판매 확대 논의…신규 시장 기회 모색알파경제 · Sep 22 15:16
- 케어젠, 글로벌 파트너와 해외 판매 확대 논의…신규 시장 기회 모색메디컬투데이 · Sep 22 15:16
-
케어젠, 두바이서 ‘Luxidase·탈모 siRNA’ 알렸다…중동 사업 확대 모색
1 more on this story · 1 outlets
- 케어젠, 두바이서 ‘Luxidase·탈모 siRNA’ 알렸다…중동 사업 확대 모색알파경제 · Sep 14 09:43